“…In 2020, Lalaoui et al [ 56 ] reviewed series and selected case reports studying epidemiological and clinical infections due to carbapenem-resistant GNB in patients with HM [ 2 , 3 , 6 , 17 , 18 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ]. In their study, resistance profiles of strains involved mainly reflected local epidemiology, and they observed that significant risk factors associated with infections with CRE included male, age around 50 years old, AL, selvage chemotherapy, neutropenia, and digestive tract colonization by carbapenem-resistant bacteria.…”